The Study of Genotypes and Result of Treatment in Hepatitis C Patients with or without HIV of Samutsakhon Hospital in 2019
Keywords:
hepatitis C, pegylated interferon(IFN) / sofosbuvir(SOF), sofosbuvir/ledipasvir(SOF/LDV), ribavirin(PR), hepatocellular carcinoma (HCC)Abstract
ABSTRACT
Objective: The aim was to study genotypes and result of treatment in hepatitis C patients with or without HIV co-infection at Samutsakhon Hospital in one year (2019).
Methods: In this descriptive retrospective study, data were collected from information drug sheets of hepatitis C patients with or without HIV co-infectionat Samutsakhon Hospital since 1 January to 31 December 2019. Analysis of the data was done by using mean, median, mode ,and range.
Result: Hepatitis C patients with or without HIV co-infection at Samutsakhon Hospital (2019) had the median age of 52 ±8 years and the median body weight of 63±16 kilograms. Males were more predominant than females (62.9% vs 37.1%) . Of all 27 patients, 44% were detected HCV viral load less than 1,000,000iu/ml. Furthurmore, all patients were examined liver fibrosis by ultrasound elastography and 22 % had value less than 8 kPa. HIV co-infection was found in 25.9 % of chronic hepatitis C patients and those patients had antiretroviral drug treatment with CD4 cell count more than 200 cell/mm3 with HIV viral load less than 50 copies/ml. All chronic hepatitis C patients in this study were without hepatitis B co-infection. In addition, 70.3% of patients had cirrhosis.
In this study, there were 3 regimens of treatment chronic hepatitis C patients, i.e., 29.6 % used sofosbuvir + peginterferon-alfa+ ribavirin, 29.6% used sofosbuvir/ledipasvir and 40.8 % used sofosbuvir/ledipasvir+ ribavirin.
Conclusions: Genotypes 1 was the most of chronic hepatitis C patients(37%). Genotype 3 and Genotype6 were found 33.3% and 29.6 % . No case of genotypes 2, 4 and 5 was detected. All of hepatitis C patients with or without HIV co-infection at Samutsakhon Hospital had EOT and SVR at 12 weeks after treatment.
References
2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis c virus genotypes. Hepatology. 2015; 61(1): 77-87.doi: 10.1002/hep.27259
3. Lwin AA, Shinji T, Khin M, et al. Hepatitis C virus genotype distribution in Myanmar: Pedominance of genotype 6 and existance of new genotype 6 subtype. Hepatology Res. 2007; 37(5): 337-45. doi: 10.1111/j.1872-034X.2007.00053.x.
4.Sunanchaikarn S, Theamboonlers A, Chongsrisawat V, et al. Seroepidemiology and genotypes of hepatitis C virus in Thailand. Asian Pac J Allergy Immunol. 2007; 25(2-3): 175-82.
5. Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem. 2013;20(30):3733-42.doi: 10.2174/09298673113209990178.
6. Nguyen NH, VuTien P, Garcia RT, et al. Response to prgylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat. 2010; 17(10): 691-7. doi: 10.1111/j.1365-2893.2009.01226.x.
7.Thomas D, Zoulim F. New challenges in viral hepatitis. Gut. 2012;61(Suppl 1):1-5.
8. Hill A, Cooke G. Hepatitis C can be cured globally, but at what cost?Science. 2014;345(6193):141-2. Doi: : 10.1126/science.1257737
9. Welsch C, Jesudian A, Zeuzem S, et al. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 2012;61(Suppl 1):i36-46.
10. Bhatia HK, Singh H, Grewal N, et al. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J PharmacolPharmacother.2014; 5(4): 278-84.doi: 10.4103/0976-500X.142464
11. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment experienced patients with cirrhosis and hepatitis Cvirus genotype 2infection. Gastroenterology. 2015;149(6):1462-70.
12. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon-alfa and ribavirin for non-cirrhotic, treatment-naïve patientswith genotypes1,2 and 3hepatitis C infection: a randomized, double-blind,phase 2 trial.Lancet Infect Dis. 2013;13(5):401-8.doi: 10.1016/S1473-3099(13)70033-1.
13.Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87. DOI: 10.1056/NEJMoa1214853
14. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al.Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patientswith genotype1:randomized,28-day, dose-ranging trial.J Hepatol. 2013;58(4):663-8.doi: 10.1016/j.jhep.2012.11.018
15. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvirandsofosbuvirfixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patientswith genotype 1hepatitis C: an open-label, randomized, phase 3 trial. Lancet Infect Dis. 2015;15(6):645-53.doi: 10.1016/S1473-3099(15)70099-X
16.Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvirand sofosbuvir, with or without ribavirin,for 12 weeks in patients with HCV virus genotype 3 or 6infection.Gastroenterology.2015;149(6):1454-61.
17.Afdha N, Reddy KR, Nelson DR, et al. Ledipasvirand sofosbuvir forpreviouslytreatedHCV genotype 1 infectionN Engl J Med.2014;370(16):1483-93.doi: 10.1056/NEJMoa1316366.
18.Afdha N,Zeuzem S, Kwo P, et al.LedipasvirandsofosbuvirforuntreatedHCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98. DOI: 10.1056/NEJMoa1402454
19.Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trail of interferon-free therapy forhepatitis C virus genotype 1. N Engl J Med. 20140; 370(3): 222-32. doi: 10.1056/NEJMoa1306227.
20.Kapol K, Lochid-amnuay S, Teerawattananon Y. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. BMC Gastroenterology. 2016; 16: 91. doi: 10.1186/s12876-016-0506-4
Downloads
Published
How to Cite
Issue
Section
License
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
